

Open to Enrollment

Preventing Asthma in High Risk Kids (PARK)

Randomized, double-blind, placebo controlled, parallel arm study with 96 week treatment phase using Omalizumab or placebo and 96 week observation phase

Study Sponsor: The National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility: The child should be between 24-47 months of age with 2-4 episodes of wheezing in the past 12 months. At least one biological parent or sibling with history of asthma or allergy.

What is requested: Monthly injection of Omalizumab or placebo, nasal swabs, saliva, blood, skin testing, environmental samples, urine, and stool sample.

Systems Biology of Early Atopy (SUNBEAM)

This is a prospective cohort study in which pregnant women (at any stage of pregnancy), the offspring's biological father, and the offspring will be enrolled and the offspring will be observed from birth to age 3 years.

Study Sponsor: The National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility: Pregnant women age 18 years or older planning to give birth at the Texas Children's Hospital Pavilion for Women who agree to enroll offspring into the study at birth.

What is requested: Clinical assessments will be conducted, questionnaire information collected, and biological and environmental samples collected on the mother, father, and child in the prenatal, perinatal, and postnatal periods of the child's life.

Vitesse

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 ug in 4-7 year old Children with Peanut Allergy

Study Sponsor: DBV

Expected start date: August 2023

Target Enrollment: 10

Eligibility: 4-7 year olds with a clinical allergy to peanuts. Must not have been on any prior peanut therapies or studies.

What is requested: A year long study of wearing and applying a daily peanut patch. Two sets of double-blind placebo controlled food challenges, once at screening and once at the end of the study. Daily diaries will be kept. Blood draws, skin prick tests, and questionnaires will be done at certain visits throughout the trial.

Improving Racial/Ethnic and Socioeconomic Diversity in our Food Allergy Program

The purpose of the study is to evaluate a program that provides allergy safe, nutritious foods to food insecure children using a recently developed online marketplace that supports patient choice in combination with 1:1 nutrition counseling.

Study Sponsor: Texas Children's Hospital and Food Equality Initiative

Eligibility: Contact staff for eligibility

What is requested: Questionnaires

For more information, please contact
foodallergynurse@texaschildrens.org or 832-824-3398

Texas
Children's
Hospital
Food
Allergy
Program
Research
Studies



Food Allergy Program
at Texas Children's Hospital*



Texas Children's
Hospital*

Open to Enrollment

FARE patient registry

A registry for food-allergic individuals and their caregivers to quickly, conveniently and privately share their food allergy experiences through simple online surveys in order to help advance food allergy research.

Study Sponsor: Food Allergy Research and Education (FARE)

Eligibility: Male or female of all ages with food allergy

What is requested: Online survey completion

EGID Studies Open to Enrollment

Outcome Measures for Eosinophilic Gastrointestinal Disease across Ages (CEGIR OMEGA)

A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG) and Colitis (EC)

Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility: Male or female 3 years of age or greater diagnosed with EoE, EG, EC, or EGE.

What is requested: Completion of questionnaires. Optional: a sample of tissue from your standard of care endoscopy and blood sample collection.

Dupilumab Eosinophilic Gastritis Study (CEGIR DEGAS)

A phase 2 randomized double-blind, placebo-controlled clinical trial to evaluate the efficacy of Dupilumab in subjects with eosinophilic gastritis

Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Expected start date: July 2021

Target enrollment: 3 patients

Eligibility: Male or female age 12 years and up with active eosinophilic gastritis as demonstrated by biopsy with a peak gastric count of ≥ 30 eos/hpf in at least 5 hpf in the gastric antrum and/or body. History by patient report of moderate to severe EG symptoms (stomach pain, stomach cramping, nausea, bloating, burning feeling in the chest, starting to eat and feeling full too quickly, loss of appetite, vomiting, or diarrhea at least 2 days per week in the 2 weeks prior to screening.

What is requested: Treatment with a shot of Dupilumab or Placebo, electronic diary completion, tissue sample from endoscopy procedure, and blood sample collection.

For more information on EGID studies, please contact:

Amanda Vega

832-824-0939

or axvega6@texaschildrens.org

Texas
Children's
Hospital
Eosinophilic
Gastrointestinal
Disease
(EGID)
Research
Studies



Food Allergy Program
at Texas Children's Hospital®



Texas Children's
Hospital®

Upcoming Research Studies

Tree Nut Oral Immunotherapy

This is an open-label, single center, randomized study. The primary objective is to determine the safety of multi-tree nut OIT versus single-tree nut OIT.

Expected start date: October 2023

Target Enrollment: 3

Eligibility: Age 4-16 years weighing at least 18.3kg, clinical allergy to at least one of the following (cashew, walnut, almond, hazelnut)

What is requested: The study will require approximately 24 visits over the course of 18 months. The participant will undergo oral food challenges, skin prick testing, bloodwork, questionnaires, and daily dosing of oral immunotherapy.

Texas
Children's
Hospital
Food
Allergy
Program
Research
Studies



Food Allergy Program
at Texas Children's Hospital*



Texas Children's
Hospital*

For more information, please contact
foodallergynurse@texaschildrens.org or 832-824-3398